Recordati

REC

IT0003828271

Pharmaceuticals

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-04-23 am EDT			5-day change	1st Jan Change
52.6 ^EUR	0.00%		+6.61%	+7.72%

Apr. 23	CVC explores options for Italy's Recordati, Bloomberg News reports	RE
Apr. 23	Mib rises; A2A on fifth bullish session in a row.	AN

Recordati Industria Chimica E Farmaceutica S.P.A. Provides Earnings Guidance for the Year 2021

May 06, 2021 at 09:26 am EDT

Recordati Industria Chimica e Farmaceutica S.p.A. provided earnings guidance for the year 2021. The Company announced the financial targets for 2021, which foresaw revenue of between 1,570 million and 1,620 million.

Latest news about Recordati

CVC explores options for Italy's Recordati, Bloomberg News reports	Apr. 23	RE
Mib rises; A2A on fifth bullish session in a row.	Apr. 23	AN
Mib above 34,000 threshold; TIM among the best	Apr. 23	AN
Stock markets in green; Italian deficit increases	Apr. 23	AN
Recordati in first quarter increases revenues by 10 percent	Apr. 22	AN
Futures bullish; car registrations drop	Apr. 18	AN
Mib rebounds as banks boost	Apr. 17	AN
Traders ignore Powell; Popolare Sondrio bullish	Apr. 17	AN
Stock markets down ahead of ECB decision	Apr. 11	AN
Mib at 34,000; oil stocks push on list	Apr. 11	AN
Recordati buys ordinary shares for nearly EUR2 million	Apr. 10	AN
Recordati takes over 23,300 ordinary treasury shares	Apr. 05	AN
Stock exchanges without momentum in opening; banking sluggish	Mar. 27	AN
Recordati buys back own shares for more than EUR1 million	Mar. 25	AN
Indexes up; Leonardo tops on Mib.	Mar. 22	AN
Futures directionless on Fed day	Mar. 20	AN
Recordati has bought back its own shares for more than EUR1 million	Mar. 19	AN
Mib queen of Europe, focus shifts to Fed	Mar. 19	AN
Recordati proposes dividend after revenue and profit growth	Mar. 19	AN
Mib veers bullish; Brembo to fourth bullish	Mar. 19	AN
Recordati bought back 14,103 of its own shares for more than EUR730,000	Mar. 13	AN
Recordati has bought back more than 32,000 of its own ordinary shares	Mar. 05	AN
Mib at peak since 2008; MPS updates annual max	Mar. 01	AN
Recordati has purchased treasury shares for more than EUR560,000	Feb. 26	AN
Europeans heading for a slightly down opening	Feb. 26	AN

Chart Recordati

Duration

Period

More charts

Company Profile

Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.; - medicines for rare diseases (32.1%). Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE MIB INDEX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Recordati: An Italian mid-cap that has everything going for it

February 02, 2024 at 05:19 am EST

More Strategies

Ratings for Recordati

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

52.6 EUR

Average target price

51.24 EUR

Spread / Average Target

-2.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
RECORDATI	+7.72%	11.19B
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
MERCK & CO., INC.	+16.38%	322B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals

Recordati

Equities

REC

IT0003828271

Pharmaceuticals

Recordati Industria Chimica E Farmaceutica S.P.A. Provides Earnings Guidance for the Year 2021

EPS Revisions